ANAC

Arctos NorthStar Acquisition Corp. (ANAC) | Rumor.io

Arctos NorthStar Acquisition

ANAC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ANAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Nov 27

The company Arctos NorthStar Acquisition Corp. ($ANAC) is considered a good project with high potential for success.
Investors are encouraged to buy and hold $ANAC, with some even predicting it will "go to the moon".
The project is seen as having quality that attracts attention, with some considering it the "best airdrop in the world".

Generated by AI

Sentiment

Of the messages about ANAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +80.95
Bearish	—	—	0%	0% -80.95

Bullish· May 16

$ANAC has been trading with a premium, which is good for the biotech sector.
A merger involving $ANAC has been completed, which could lead to further growth in the sector.
$ANAC's recent price increase is likely due to a possible bidding war, with some reports suggesting a bid at $139.

Bearish· May 16

The acquisition of $ANAC by Pfizer for $99.25 may be a bad deal for investors who purchased the stock at higher prices.
The stock has already experienced significant losses, with one investor down 80% before the latest decline and another down 40% for the year.
Shorting the stock may be a high-risk strategy, as evidenced by one investor who was short and missed out on a significant decline.

Generated by AI

Topics

Of the messages about ANAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	95.74%	95.74%	95.74%	95.83%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	4.26%	4.26%	4.26%	4.17%
Technical Analysis	0%	0%	0%	0%

May 16

Pfizer has agreed to buy Anacor Pharmaceuticals for $99.25 per share in cash for a transaction value of $5.2 billion.
The acquisition diversifies Pfizer's portfolio and adds Anacor's eczema treatment, crisaborole, which could potentially generate $2 billion in revenue.
Anacor's drug development process and potential revenue growth are key factors in the acquisition, making it a significant deal in the biotech industry.

Generated by AI

Community

Of the messages about ANAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Also Discussed

Investors talking about ANAC also mention

#	Name	Attention
1	GBRG - Goldenbridge Acquisition Limited	——
2	TLGA - TLG Acquisition One Corp.	——
3	DBDR - Roman DBDR Tech Acquisition Corp.	——
4	CSTA - Constellation Acquisition Corp I	——
5	BCTG - BCTG Acquisition Corp.	——
6	OCAXU - OCA Acquisition Corp.	——
7	CPTK - Crown Proptech Acquisitions	——
8	ARBG - Aequi Acquisition Corp.	——
9	PRPC - CC Neuberger Principal Holdings III	——
10	HYAC - Haymaker Acquisition Corp. III	——